15256-10-7

Usage

Uses

Used in Pharmaceutical Industry:
4-[(AMMONIOOXY)METHYL]-1,2-DICHLOROBENZENE CHLORIDE is used as an inhibitor for indoleamine 2,3-dioxygenase-1 (IDO1) for its potential therapeutic applications in the treatment of cancer, chronic viral infections, and other diseases characterized by pathologies involving IDO1 overexpression.
Used in Cancer Treatment:
4-[(AMMONIOOXY)METHYL]-1,2-DICHLOROBENZENE CHLORIDE is used as an anticancer agent, targeting IDO1, which plays a role in tumor growth and immune evasion. By inhibiting IDO1, 4-[(AMMONIOOXY)METHYL]-1,2-DICHLOROBENZENE CHLORIDE may help in the development of novel cancer therapies and improve the effectiveness of existing treatments.
Used in Chronic Viral Infections Treatment:
4-[(AMMONIOOXY)METHYL]-1,2-DICHLOROBENZENE CHLORIDE is used as an antiviral agent, targeting IDO1, which is involved in the pathogenesis of chronic viral infections. Inhibiting IDO1 may help in the development of new treatments for such infections by modulating the immune response and reducing viral persistence.
Used in Other Disease Treatments:
4-[(AMMONIOOXY)METHYL]-1,2-DICHLOROBENZENE CHLORIDE is used as a therapeutic agent for diseases characterized by pathologies involving IDO1 overexpression. By targeting IDO1, 4-[(AMMONIOOXY)METHYL]-1,2-DICHLOROBENZENE CHLORIDE may help in the development of novel treatments for a range of conditions beyond cancer and chronic viral infections.

InChI:InChI=1/C7H7Cl2NO.ClH/c8-6-2-1-5(4-11-10)3-7(6)9;/h1-3H,4,10H2;1H

Upstream product

• 38936-82-2 2-(3,4-dichlorobenzyloxy)isoindole-1,3-dione 
• 84772-12-3 O-[(3,4-dichlorophenyl)methyl]hydroxylamine 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 1805-32-9 3,4-dichlorobenzyl alcohol 
• 102-47-6 3,4-Dichlorophenylmethyl chloride 

Downstream Products

• 1174758-21-4 tert-butyl N-(3,4-dichlorobenzyloxy)carbamate 
• 880471-91-0 C₁₅H₁₀Cl₃F₃N₂O₃S 
• 880473-83-6 C₂₁H₁₄Cl₃F₃N₂O₃S 
• 133327-09-0 4-(3,4-Dichlor-benzyloxy)-allophansaeure-(3,4-dichlor-benzylester) 

Relevant academic research and scientific papers

Synthesis and antibacterial evaluation of (E)-1-(1H-indol-3-yl) ethanone O-benzyl oxime derivatives against MRSA and VRSA strains

Infections caused due to multidrug resistant organisms have emerged as a constant menace to human health. Even though numerous antibiotics are currently available for treating infectious diseases, a great number of bacterial strains have acquired resistance to many of them. Among these, infections caused due to Staphylococcus aureus are predominant in adult and paediatric population. Indole is a prominent chemical scaffold found in many pharmacologically active natural products and synthetic drugs. A number of oxime ether containing compounds have attracted attention of researchers owing to their interesting biological properties. Current work details the synthesis of indole containing oxime ether derivatives and their evaluation for antimicrobial activity against a panel of bacterial and mycobacterial strains. Synthesized compounds demonstrated good to moderate activity against drug-resistant S. aureus including resistant to vancomycin. Among all, compound 5h was found to possess potent activity against susceptible as well as MRSA and VRSA strains of S. aureus with MIC of 1 μg/mL and 2–4 μg/mL respectively. In addition, compound 5h was found to be non-toxic to Vero cells and exhibited good selectivity index of >40. Further, 5h, E-9a and E-9b possessed good biofilm inhibition against S. aureus. With these assuring biological properties, synthesized compounds could be potential prospective antimicrobial agents.

O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1

Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a potent sub-micromolar inhibitor of IDO1. Structure-activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications.

Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives

Novel trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo or ex vivo.

Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials

A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine WR-99210 (8s), have been prepared. Several of them, such as 5b (PS-33) and 5m (PS-26), maintain or exceed the in vivo activity of PS-15 while not requiring the use of highly regulated starting materials. The putative diaminotriazine metabolites of these new analogues (compounds 8) have also been prepared and shown to maintain the activity against resistant P. falciparum strains. The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.